Ingeborg H. Vriens
Maastricht, LI, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Real-world implementation of pertuzumab from 2013 to 2023 for de Novo HER2-positive metastatic breast cancer in the Netherlands: a population-based study.
Journal: Breast (Edinburgh, Scotland)
Published: March 30, 2026
Prenatal cell-free DNA testing of women with pregnancy-associated cancer: a retrospective cross-sectional study.
Journal: The Lancet regional health. Europe
Published: May 08, 2024
Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial.
Journal: Breast cancer research and treatment
Published: May 05, 2024
Outcomes of female fertility preservation with cryopreservation of oocytes or embryos in the Netherlands: a population-based study.
Journal: Human reproduction (Oxford, England)
Published: March 11, 2024
Results of an international survey on the current organization of care for pregnant women with cancer.
Journal: Acta obstetricia et gynecologica Scandinavica
Published: September 22, 2023
Considerations of breast cancer survivors to return for embryo transfer after fertility preservation: A qualitative study.
Journal: European journal of obstetrics, gynecology, and reproductive biology
Published: July 12, 2023
The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry.
Journal: Breast cancer research and treatment
Published: July 11, 2023
The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.
Journal: JNCI cancer spectrum
Published: July 05, 2023
Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial.
Journal: EClinicalMedicine
Published: December 20, 2022
Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry.
Journal: Breast cancer research and treatment
Published: October 17, 2022
The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.
Journal: Breast cancer research and treatment
Published: October 12, 2021
Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.
Journal: Breast cancer research and treatment
Published: January 19, 2021
Last Updated: 09/26/2026